X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Twelve Digit National Drug Code Gets Proposed By The FDA

Content Team by Content Team
8th February 2023
in News, Packaging & Logistic
Usual Pharma Compliance Issues Noted In FDA Warning Letters

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

All labelling pertaining to the products that carry the national drug code will have to be updated if in case the FDA finalises its proposed policy to expand the numbers from 10 to 12 digits. There will be some cases where a label will be required to allow more space for the code. The aim of the proposed rule which is revising the National Drug Code Format and drug level barcode requirements, is to standardise the NDC format, expand the available code pool, and also push for an increase in the number of barcodes that are acceptable.

Lengthening of the codes is essential since the supply of the five-digit labeller code will run out in a matter of 10–15 years.

The rule that is proposed specifies that a 12-digit NDC includes three segments, besides a 6-digit labeller code, 2-digit package code, and 4-digit product code. The effective date is most likely going to be 5 years after the publication of the final rule, which will be followed by a 3-year transition time so as to convert the existing 10-digit code to 12 digits. During this time, all the stakeholders involved will have to run the systems that are capable of taking care of both 10- and 12-digit NDCs. 1

The code change will also have to have employee trainings and an updated software. As per the estimates made by the FDA, this change is going to cost the industry anything between $43.1 million and $136.3 million. 2

Numerous commentors have agreed to the fact to lengthen the NDC but at the same time have concerns over the timeline as well as the number of stakeholders who will rely on the NDC, besides packaging, system change, and also software and cost projections.

If it is finalized, then the change will be noticed across the supply chain. Because of the number of systems and parties as well as the processes that would be affected, the GS1 US compared the impact to the Y2K transition in 2000. As per GS1, there are majorly three categories of systems which will get impacted by NDC format change namely barcoding systems, the organizational interfaces and the existing system used within the industry. The industry will not be able to use the linear UPC barcode because of the increased length to 12 digits. This will have repercussions, as there will then be a wider demand to use the 2D DataMatrix barcode within a certain space.

The director of sales and marketing of one of the companies that specialises in pharmaceutical contract packaging says that the logistics will have to be managed in order to ensure that there is no disruption when it comes to the supply chain. Also, the potential, as far as supply chain disruption is concerned, isn’t just limited to the presence of pharmaceutical products.

Previous Post

NICE Urged To Make The Kidney Cancer Treatment A Priority

Next Post

30% Lesser Side Effects, Thanks To The DNA Medication Pass

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

30% Lesser Side Effects, Thanks To The DNA Medication Pass

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In